Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-de®cient Saos2 osteosarcoma cells. A p53 binding site residing at position 7265/7239 in the EGF-R proximal promoter has also been identi®ed. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53
Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-de®cient Saos2 osteosarcoma cells. A p53 binding site residing at position 7265/7239 in the EGF-R proximal promoter has also been identi®ed. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53
A1a143 enhanced the EGF-R core promotor activity in cells that were either p53-de®cient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identi®ed a wild-type p53 responsive 62 bp region residing at position 7167/7105. The 7167/7105 segment was responsive only to wild-type p53 but not to mutant p53
A1a143 or p53
His273
. The 7167/7105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp 7167/7105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identi®ed an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position 7167/7105 and is proximal to recently identi®ed p53 binding element located at position 7265/7239 in the EGF-R promotor.
Keywords: p53; EGF-R promotor; transactivation A large body of genetic, biochemical and physiological evidence implicates p53 activity in regulation of numerous processes including cell growth, differentiation, senescence, apoptosis and angiogenesis (see for review: Bates and Vousden, 1996) . The best studied and perhaps the central role of p53 is its ability to induce growth arrest by activating G1 checkpoint (see for review: Bates and Vousden, 1996; Vogelstein and Kinzler, 1992; Levine, 1993) . Exactly how p53 might play so many apparently diverse roles, remains unclear. One recurring theme that emerges from the wealth of information on p53 is that p53 appears to modulate the function of important cellular genes (see for review: Bates and Vousden 1996; Vogelstein and Kinzler, 1992; Levine, 1993) . The potential of p53 to directly bind DNA in a sequence speci®c manner and to transactivate the p53 downstream genes is now well documented. p53 has also been shown to suppress the expression of a number of TATA-containing gene promoters independently of direct DNA binding (Deb et al., 1992; Mack et al., 1993) . p53 contains a central DNA binding region, a transactivation domain and an oligomerization domain (see for review: Ko and Prives, 1996) . The p53 consensus DNA binding sites have been described and include two copies of the 10 bp sequence motif 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3' with 0 ± 13 bp spacer between the half sites Funk et al., 1992) . p53 is believed to bind to each half site as a dimer and thus 2 copies of the binding site allow p53 to bind to its consensus sequence as a tetramer El-Deiry et al., 1992; Funk et al., 1992) . Given the variety of cellular processes in which p53 activity has been implicated, the number of genes that are directly regulated by p53 is suprisingly low. Some of the p53 target genes identi®ed to date are, p21 WAF1/CIP1 (El-Deiry et al., 1993) MDM2 (Barak, et al., 1993) GADD45 (Kastan et al., 1992) , BAX (Miyashita et al., 1995) Rb (Osifchin et al., 1994) , PCNA (Jackson et al., 1994) , TGF-a (Shin et al., 1995) , IGFBP3 (Buckbinder et al., 1995) , Thrombospondin (Dameron et al., 1994) and cyclin G (Okamoto and Beach, 1994) . However, the number of p53 regulated genes is estimated to be far greater and thus many p53 regulated genes still remain to be identi®ed.
Wild-type and mutant p53 enhancement of EGF-R gene promoter activity in Saos-2 osteosarcoma cells has been reported in a recent study (Deb et al., 1994) . In another study, however, Ueba et al. (1994) were unable to ®nd wild-type or mutant p53 regulation of EGF-R promoter activity in SKHepG2 hepatocarcinoma cells. Thus, wether in fact EGF-R is a p53 target gene remains to be fully established. More recently, the former group (Ludes-Meyers et al., 1996) has identi®ed a p53-binding site within the EGF-R proximal promoter. This p53 binding site resides at position 7265/7239 and contains four mismatches from the consensus p53-binding element (Ludes-Meyers et al., 1996) . Based on their ®ndings Ludes-Meyers et al. (1996) concluded that wild-type p53 transcriptionally regulates EGF-R gene via direct DNA binding.
EGF and TGF-a are potent autocrine growth factors and mediate their mitogenic signals via EGF-R (see for review : Carpenter, 1987 , Fantl et al., 1993 . EGF-R is a transmembrane receptor with tyrosine kinase activity; the ligand activated EGF-R activates signaling cascades involving downstream intracellular molecules such as ras, c-RAF and MAP kinases (see for review : Carpenter, 1987; Fantl et al., 1993) . Proper regulation of EGF-R is vital for maintaining cellular homeostasis since alterations in the EGF-R structure/ function have been reported to be oncogenic (Stoscheck and King, 1985 ; see for review : Carpenter, 1987; Fantl et al., 1993) . Ligand independent activation of EGF-R, in response to adverse stresses such as radiation, alkylating agents and oxidants has been documented (Sachsenmaier et al., 1994; Warmuth et al., 1994; Minden et al., 1994; Ozbun and Butel, 1995; Schmidt-Ullrich et al., 1994) . Some of the same stresses that activate EGF-R and its downstream signaling cascades have also been shown to activate p53 and its downstream signaling events (reviewed in: Hollander and Fornace, 1995) . Thus the regulation of EGF-R by p53, if true, would highlight the existence of a crosstalk between the p53 and EGF-R signaling pathways. It is, therefore, important to establish that EGF-R gene is indeed one of the bona ®de targets of p53. p53 has already been shown to induce TGF-a gene promoter activity by directly binding to its cognate responsive element within TGF-a gene promoter region (Shin et al., 1995) . TGF-a is a ligand for EGF-R; evidence that p53 also regulates EGF-R would further strengthen the notion that both the ligand and the receptor are coordinately controlled.
We tested the eect of exogenous wild-type and mutant p53 on the EGF-R promoter activity in cells with wild-type, mutant and null p53 backgrounds. The proximal 771 bp region of the human EGF-R promoter harbors the core elements for the optimal promoter activity and was placed upstream of a CAT reporter gene (pERCAT-6, Figure 1 ) (Johnson et al., 1988) . The pERCAT-6 reporter vector and the wildtype or the mutant p53
A1a143 expression vectors were transiently cotransfected into four dierent cells lines with varying status of endogenous p53. MCF-7 is a breast carcinoma cell line and harbors wild-type p53 (Sheikh et al., 1994 and refs. therein) while T47D is a breast carcinoma cell line with only one mutant p53 allele (Sheikh et al., 1994 and refs. therein) . The SKOV3 and H1299 are ovarian and lung carcinoma cell lines respectively and both have a null p53 background (Zhan et al., 1994) . Approximately 48 h after transfection CAT assays were performed on the lysates obtained from these cell lines. Wild-type p53 reproducibly enhanced the EGF-R core promoter activity in all the cell lines tested. The hot spot mutant p53 143A1a also enhanced the EGF-R promoter activity and its eect was more pronounced than the eect of wild-type p53 in MCF-7 and T47D cell lines. In SKOV3 and H1299 cells the eect of p53 143A1a was weaker than the eect of wild-type p53. Figure 2 shows the representative results of wild-type and p53 143A1a regulation of EGF-R core promoter activity in dierent cell lines; the overall results are summarized in Table 1 . These results demonstrate that the EGF-R gene promoter is a bona ®de target of p53. It is interesting that p53 143A1a mutant functions as transdominant negative mutant as can be evidenced by its ability to abrogate the potential of endogenous wildtype p53 to activate the pG 13 -CAT reporter activity in MCF-7 cells ( Figure 2 ). The pG 13 -CAT reporter vector carries 13 copies of p53 binding site and is predominantly regulated by wild-type p53. These results, therefore, highlight the dierences in the mode 
The transactivation by wild-type and mutant p53
A1a143 from pERCAT-6 and pG 13 -CAT. Logarithmically growing cells were transfected in 100 mm plates with 5mg each of pERCAT-6 and either wild-type or mutant p53 expression vector; vectortransfected cells received the pCMV-expression vector devoid of p53 cDNA inserts (empty vector). Cells were harvested 48 h posttransfection and CAT assays were performed as previously described (Sheikh et al., 1994) p53 regulation of the epidermal growth factor receptor M Saeed Sheikh et al of action via which the wild-type and mutant p53 143A1a appear to regulate the EGF-R promoter.
To delineate the wild-type p53 responsive region(s), we utilized dierent deletion fragments of EGF-R promoter placed upstream of CAT reporter gene. H1299 cells (with p53 null background) were transiently cotransfected with EGF-R reporter constructs and the wild-type p53 expression vector. Cells were harvested approximately 48 h post-transfection; aliquots of transfected cells from each sample were processed for immuno¯uorescent staining to con®rm the expression and subcellular localization of exogenous p53. The remaining transfected cells in each set were processed to determine CAT reporter activity. The representative photomicrographs shown in Figure  3 demonstrate that the cells transfected with the wildtype p53 expression vector exhibit characteristic nuclear p53 staining while the vector only transfected cells were devoid of such staining pattern. Thus, the exogenous p53 was expressed in these transiently transfected cells and was correctly processed within the nucleus (Figure 3) .
The representative results in Figure 4 illustrate the eects of wild-type p53 on the activity of various Ala143 expression vectors. CAT assays were performed as mentioned in legend to Figure 2 . Since wild-type and mutant p53 regulate the viral promoters (Ginsberg et al., 1991; Deb et al., 1992) , it was not possible to use pSVbGal or pRSVbGal reporter vectors to normalize for the dierences in transfection eciencies. For quantitative comparison the vector transfected and p53 transfected samples containing equal protein concentrations were analysed in CAT assays and the experiments were repeated several times. The p53-mediated fold increase in CAT activity over controls is mentioned as follows: +++= sevenfold and higher; ++= 3 ± 6-fold; += twofold and less Vector-transfected p53-transfected Figure 3 Immuno¯uorescent detection of exogenous p53 in transiently transfected p53-de®cient H1299 cells. Cells were transfected with the various deletional constructs of EGF-R promoter and the wild-type p53 expression vectors. Cells were harvested 48 h post transfection and an aliquot from each sample was seeded in tissue culture slides. The remaining cells from each sample were processed to determine CAT reporter activity as shown in Figure 4 . Cells seeded in tissue culture slides were incubated at 378C for several hours and then processed for immuno¯uorescent staining as described previously (Sheikh et al., 1996) . p53 speci®c 1801 monoclonal antibodies were used to detect exogenously introduced wild-type p53 and results of one representative group is shown
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pERCAT-14 pERCAT-13 pERCAT-6 pERCAT-9 p53 regulation of the epidermal growth factor receptor M Saeed Sheikh et al deletion fragments of EGF-R promoter. Consistent with the preceding results, wild-type p53 induced EGF-R promoter activity from the 771 bp proximal promoter region. However, the deletion of sequence distal to nucleotide 7384 (pERCAT-9) did not alter the EGF-R promoter responsiveness to wild-type p53, suggesting that the wild-type p53 responsive region appears to reside within the proximal 384 bp sequence. Wild-type p53 was unable to induce the EGF-R promoter activity from the proximal 104 bp region (Deb et al., 1994) implying that the p53 responsive region may reside between nucleotides 7384 and 7105. Indeed a 62 bp EGF-R promoter fragment corresponding to nucleotide sequence 7167/7105 was responsive to transactivation by wild-type p53. However, when a deletion representing the nucleotide sequence 7167/7105 was introduced into the construct carrying 771 bp proximal EGF-R promoter sequence (pERCAT-13), the p53 induction was not lost. Given that the EGF-R promoter fragment in the pERCAT13 construct harbors the recently identi®ed p53-binding site at position 7265/7329, the above results were not surprising. Taken together these ®ndings suggest that wild-type p53 appears to regulate the EGF-R promoter activity form more than one independent sites. The consensus sequence for the p53 binding site has been de®ned as two copies of the 10 bp sequence motif 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3' with a 0 to 13 bp spacer between the two sites (El Deiry et al., 1992; Funk et al., 1992) . p53 is believed to bind to each halfsite as a dimer and the two sites aord p53 binding as a tetramer (Wang et al., 1995 and refs. therein) . Analysis of the 62 bp (7167/7105) EGF-R promoter sequence revealed that indeed it contains several 10 bp p53 consensus half-sites. One 10 bp half-site residing at position 7164/7155 matches perfectly with the consensus sequence while another half-site containing only two mismatches from the consensus sequence is present at position 7125/7116 and is separated from the ®rst site by 29 bp (Figure 5 ). Three additional halfsites bearing weaker homology with the consensus sequence can also be identi®ed in the 62 bp 7 167/ 7105 region ( Figure 5 ). It is interesting that the 62 bp p53 responsive EGF-R promoter region resembles the p53 responsive region of the human BAX gene in that the 39 bp p53 responsive BAX promoter region also contains one perfect p53 consensus half-site and three imperfect half-sites bearing weaker homologies with the p53 consensus binding element (Miyashita and Reed, 1995) . The imperfect half-sites in human BAX gene promoter are also present at a variable distance from the perfect half-site (Miyashita and Reed, 1995) .
We next tested whether p53 can directly bind to the oligonucleotides representing the 62 bp 7167/7105 EGF-R promoter sequence. Electrophoretic mobility shift assays (EMSAs) were performed using the radiolabeled double-stranded synthetic oligonucleotides and the baculovirus-expressed human wild-type p53. We also included anti-p53 monoclonal antibodies 421 and DO1 in these experiments since these antibodies are known to alter the p53 conformation to enhance its DNA binding ability. From the representative results illustrated in Figure 6a , it is clear that the 7167/7105 fragment exhibited two predominant retarded complexes only when the baculovirus Sf9 cell lysates expressing human wildtype p53 were used; the same probe did not exhibit similar complexes when the lysates from the Sf9 cells expressing human Gadd45 were used. Furthermore, the mock infected cell lysate also did not exhibit formation of the same retarded complexes (data not shown) con®rming that the two predominant retarded complexes formed on the 7167/7105 oligonucleotides were indeed speci®c and were due to the presence of wild-type p53. In competition experiments excess unlabeled oligonucleotides corresponding to p53-binding site of human Gadd45 gene competed for these complexes (data not shown) which further substantiate the presence of p53 in the retarded complexes.
The DNA binding potential of wild-type p53 can be enhanced upon addition of anti-p53 monoclonal antibodies in the gel shift experiments (Hupp et al., 1992) . However, p53 also exists in latent conformation and does not always require anti-p53 antibodies for speci®c DNA binding (Ullrich et al., 1992; Fiscella et al., 1994; Hupp and Lane, 1995) . The monoclonal antip53 antibodies 421 and DO1 minimally enhanced the intensity of the complexes formed on the 7167/7105 oligonucleotides (Figure 6a ). Given the complex nature of the 7167/7105 segment it appears likely that the retarded complexes formed on this segment may also contain other factors that may interact with p53 to alter its conformation and the DNA binding ability. Thus the lack of monoclonal antibodies' ability to grossly enhance the intensity of the retarded complexes formed on the oligonucleotides corresponding to 7167/7105 sequence may re¯ect the fact that wildtype p53 may not require further stabilization to bind to these oligonucleotides. In a recent study Hupp and Lane (1995) have in fact demonstrated that the baculovirus expressed wild-type p53 exists in dierent biochemical forms; one form existing in an activated conformation is insensitive to anti-p53 antibodies in DNA and protein binding assays and exhibits high anity sequence speci®c DNA binding.
We next tested whether the two candidate p53 consensus halfsites within the 7167/7105 EGF-R segment would bind to wild-type p53. We synthesized synthetic oligonucleotides carrying these two half-sites placed in tandem without intervening sequence [5'- These oligonucleotides were tested in EMSAs utilizing the baculovirus expressed wild-type p53. As shown in Figure 6b these oligonucleotides exhibited one major retarded complex most likely representing p53 since its binding was further enhanced when the 421 and DO1 anti-p53 monoclonal antibodies were included in the experiments. Thus the two consensus half-sites present within the 62 bp p53 responsive EGF-R promoter segment indeed exhibit p53 binding. Whether other sequences within this 62 bp segment that exhibit weaker homology to the p53 consensus binding elements can also bind to p53 remains unclear. However, the presence of one perfect, one near perfect and three imperfect p53 consensus half-sites within this p53 responsive segment may not be just coincidental.
Further studies are required to elucidate the relative contribution of these half-sites in conferring p53 responsiveness upon the 7167/7105 segment. The 7167/7105 EGF-R promoter segment exhibits complex characteristics. It contains 4 transcription start sites as well as the binding sequences for AP2, SP1 and p53. Furthermore, this minimal promoter segment also functions as a basal promoter. Thus the p53 regulation of EGF-R promoter from the 7167/7105 site may also involve interaction with other factors of the basic transcriptional machinery. In conclusion we have presented several lines of evidence to demonstrate that p53 regulate EGF-R promoter from the 7167/7105 site and that p53 regulation from this site appears to involve direct transcriptional activation. For example, (i) the 7167/ 7105 segment when placed upstream of a promoterless CAT gene was sucient to confer p53 responsiveness, (ii) the mutant p53
Ala143 or p53 his273 did not activate the reporter activity from the same segment (data not shown), (iii) the sequence analysis reveals the presence of several canonical p53 binding half-sites, (iv) in EMSAs only the wild-type p53 expressing baculovirus cell extract exhibited shifted complexes on the radiolabeled 7167/7105 segment; the extracts prepared from the baculovirus Sf9 cells expressing GADD45 or mock infected cells did not exhibit the same shifted complexes on 7167/7105 probe. Furthermore, these shifted complexes could be speci®cally competed by excess unlabeled oligonucleotides containing p53 binding elements, (v) ®nally the isolated canonical p53 binding half-sites from the 7167/7105 region also exhibited p53 binding potential. Thus, our results coupled with the recent report by Ludes-Meyers et al., (1996) demonstrate that the human EGF-R promoter is a bona ®de target of p53 and that p53 regulates EGF-R promoter from more than one independent site. p53 regulation of gene promoters from more than one sites is not without precedence. Recently TGF-a (which is a ligand for the EGF-R) gene promoter region was shown to be regulated by wild-type p53 from two independent sites (Shin et al., 1995) . p53 also induces the p21 WAF1/ CIP1 gene promoter activity from two p53 binding sites (El-Deiry et al., 1993) . IGFBP3 gene also contains two p53 binding sites (Buckbinder et al., 1995) .
Increased production of growth factors and their receptors results in enhanced proliferation of cells (see for review ; Carpenter, 1987; Fantl et al., 1993) . Aberrant regulation of growth factors and their receptors has been implicated in malignant transformation (Stoscheck and King, 1985 ; see for review : Carpenter, 1987; Fantl et al., 1993) . Mutational inactivation of p53 also results in tumorigenesis (see for review: Bates and Vousden, 1996; Vogelstein and Kinzler, 1992; Levine, 1993) . Evidence suggests that certain types of p53 mutants have a transforming potential (the gain of function mutants) and their activation can lead to malignant progression (Zambetti and Levine, 1993 ). Our results demonstrate that the dominant negative mutant p53 143A1a also enhanced EGF-R promoter activity. Mutant p53 regulation of EGF-R appears speci®c since the p53 143A1a mutant p53 dierentially regulated the pG 13 -CAT and the EGF-R promoter activity in the same cells. Our results are in agreement with those reported by Ludes-Meyers et al. (1996) demonstrating that various tumor derived mutant p53 were able transactivate the EGF-R promoter. Thus the upregulation of EGF-R promoter by mutant p53 highlights a pathway via which the gain of function mutants of p53 may partly exhibit their oncogenic potential. Transcriptional activation of basic ®broblast growth factor (FGF) gene by mutant p53 has been demonstrated (Ueba et al., 1994) . FGF is known to play a critical role in malignant transformation and progression (Ueba et al., 1994 and refs. therein) . Mutant p53 regulation of MDR1 gene promoter activity has also been documented (Zastawny et al., 1993) . It was suggested that mutant p53-mediated transcriptional upregulation of MDR1 might be a mechanism via which cells acquire the more aggressive multidrug resistant phenotype (Zastawny et al., 1993) . Although the mutant p53 regulation of EGF-R promoter activity appears to ®t the dogma, the physiological signi®cance of wild-type p53 regulation of EGF-R remains unclear. It is known that wild-type p53 induces apoptosis (reviewed in: Bates and Vousden 1996) . EGF or TGF-a treatment of EGF-R overexpressing cells results in induction of apoptosis (Armstrong et al., 1994; Santon et al., 1986) . Wild-type p53 also transcriptionally upregulates the TGF-a expression (Shin et al., 1995) . It is well documented that EGF-R activates mitogen-activated (MAP or ERKs) as well as stress-activated (SAP or JNKs) kinases (Minden et al., 1994) . The activation of ERKs and JNKs can be coupled or can occur separately (Minden et al., 1994) . Recent evidence implicates JNK activation in induction of apoptosis (Chen et al., 1996) . It is, therefore, possible that part of the wild-type p53-mediated apoptotic signals might be transduced via EGF-R. Further studies are indicated to investigate in detail the molecular basis of the cross-talk between the p53 and EGF-R-mediated signal transduction pathways.
